Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tuo Wei has a total of 325 co-authors. Here are the top co-authors by number of shared publications:

  • Qiang Cheng

    Department of Biomedical Engineering College of Future Technology Peking University Beijing China

    28 shared publications
  • Xing-Jie Liang

    CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, Beijing 100190, PR China

    12 shared publications
  • Daniel John Siegwart

    Department of Biomedical Engineering, Program in Genetic Drug Engineering, The University of Texas Southwestern Medical Center, Dallas, USA

    11 shared publications
  • Juan Liu

    CAS Center for Excellence in Nanoscience, Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, and Laboratory of Controllable Nanopharmaceuticals, National Center for Nanoscience and Technology of China, Beijing 100190, China

    11 shared publications
  • Xing-Jie Liang

    9 shared publications
  • Zicai Liang

    9 shared publications

Latest Publications

  • Discovery and engineering of avian R2 retrotransposons for all-RNA-mediated targeted DNA integration in human cells

    by Yangcan Chen, Yanping Hu, Shengqiu Luo, Bangwei Mao, Na Tang, Chenxin Wang, Yuze Wang, Hanyu Bai, Xinge Wang, Changxian Peng, et al.

    To discover unknown retrotransposons for genomic integration in human cells, we searched 1,139 avian genomes, identified 159 avian R2 retrotransposons and characterized conserved/nonconserved sequence features in their proteins and untranslated region elements. Engineered variants of these retrotransposons achieved up to 60% site-specific gene integration across human primary cells. This work expands the avian R2 resource and provides additional tools for all-RNA-mediated genome editing.

  • Engineered lipid nanoparticles for in vivo and durable editing of haematopoietic stem cells within humanized mice

    by Jingjing Du, Zijin Luo, Dan Xie, Yan Chen, Ming Yang, Qiang Li, Lisha Wang, Lu Han, Yiming Zhang, Haiwei Li, et al.


  • Nose-to-Brain Delivery of mRNA-Loaded Lipid Nanoparticles Bypasses the Blood–Brain Barrier for Effective Brain Disease Therapy

    by Xiaolu Yu, Xiao-Meng Deng, Yi Lin, Hongyu Ren, Lu Jia, Yanan Meng, Fan Liu, Qiang Cheng, Zhao-Qian Teng, Tuo Wei

    MRNA-loaded lipid nanoparticles (mRNA-LNPs) show great therapeutic potential, but their use in central nervous system (CNS) disorders is limited by poor blood–brain barrier (BBB) penetration. Intranasal (IN) administration can bypass the BBB via olfactory/trigeminal pathways, enabling direct brain targeting and rapid screening of brain-specific lipid nanoparticles (LNPs). Using a peptide-based ionizable lipid platform, we systematically evaluated how LNP surface charge affects IN brain delivery and found that positively charged mRNA-LNPs produced superior brain transfection. Iterative in vivo screening yielded an intranasal brain-targeting LNP (INBT LNP) that efficiently traverses the olfactory and trigeminal nerves, drives brain-specific mRNA expression, and minimizes off-target expression in peripheral organs. Co-delivery of mRNAs encoding brain-derived neurotrophic factor (BDNF) and interleukin-10 (IL-10) using INBT LNPs significantly reduced neuroinflammation, inhibited neuronal death, and improved cognition in a repetitive mild traumatic brain injury (rmTBI) mouse model. Overall, this work establishes a noninvasive, patient-compliant, intranasal mRNA-LNP platform for brain delivery, offering a promising therapeutic strategy for TBI and other CNS disorders.


  • Correction to “Hydrogen Bond-Assisted Two-Component Lipid Nanoparticles for Spleen-Specific mRNA Delivery”

    by Qiu Wang, Yi Lin, Zijin Luo, Jiahui Xiao, Keqing Xu, Xiaolu Yu, Yanan Meng, Mengyao Li, Hongyu Ren, Fan Liu, et al.

  • Open Access

    Polyketal-conjugated tafluprost microparticles enable long-acting glaucoma therapy

    by Haiping Zhong, Tuo Wei, Xueyan Zhou, Na Yu, Yoshiyuki Nakagawa, Claudia Santamaria, Akiva Gordon, Weiping Wang, Jingqing Mu, Changyou Zhan, et al.

    Long-acting formulations are increasingly sought after for the management of chronic diseases. Drug-conjugated microparticles with degradation-controlled release present a promising modular extended-release platform that can be delivered through minimally invasive approaches. However, many conventional drug-conjugated microparticles have relatively short durations of release and substantial release of pharmacologically inactive drug-conjugated oligomers. Here, we present surface-erodible, drug-conjugated polyketal microparticles for extended release of unmodified pharmacologically active drug. Microparticles made of a polyketal conjugated to the anti-glaucoma agent tafluprost initially release unmodified tafluprost, then about two weeks later predominantly release the biologically active tafluprost acid due to the mildly base-catalyzed hydrolysis of tafluprost, with a cumulative total drug release of ~78% over 540 days in vitro. Notably, no detectable drug-conjugated oligomers are found in release medium. Tafluprost-polyketal conjugate microparticles that further encapsulate unconjugated tafluprost reduce intraocular pressure for approximately 3 months after subconjunctival injection in ocular normotensive female rats, exhibiting a low grade of tissue reaction, no retinal abnormalities or systemic side effects, and enhanced intraocular pressure-lowering efficacy compared with a long-acting bimatoprost-loaded biodegradable implant in an ocular hypertensive rat model. Our findings have broad implications in advancing extended drug delivery systems.


  • Systèmes innovants de délivrance de médicaments basés sur des nanomicelles pour le traitement du cancer

    by Tuo Wei

    Systèmes innovants de délivrance de médicaments basés sur des nanomicelles pour le traitement du cancer: Une faible biodisponibilité et une haute toxicité des médicaments anticancéreux, ajoutées à une résistance aux médicaments, constituent des obstacles majeurs pour le traitement du cancer. L'application des nanotechnologies pour la délivrance de médicaments est largement pressentie pour aborder ces problèmes. Premièrement, nous avons utilisé un peptide CRGDK comme ligand spécifique pour les cellules cancéreuses que nous avons conjugué au DSPE-PEG2000 pour préparer les nanomicelles encapsulant le médicament anticancéreux doxorubicine. Le peptide CRGDK conjugué aux nanomicelles provoque la liaison aux récepteurs à NRP-1, conduisant à l'absorption cellulaire spécifique et à l’amélioration de l'activité anticancéreuse in vitro. Les résultats in vivo ont également confirmé que les nanomicelles décorées de CRGDK pourraient efficacement pénétrer et s’accumuler dans les tumeurs profondes.Deuxièmement, nous avons a été consacrée à la mise au point de nanomicelles originales utilisant un dendrimère amphiphile (AmDM). Ces nanomicelles sont capables d’encapsuler efficacement la doxorubicine. Les taux de remplissage de ces nanomicelles sont extrêmement élevés. Ces nanomicelles montrent une efficacité supérieure à la doxorubicine libre et ceci sur divers types de cellules cancéreuses. De plus, ce mécanisme de pénétration cellulaire permet à ces nanomicelles de contourner le relargage du médicament médié par la pompe à efflux glycoprotéine, et ainsi surmonter la résistance à la doxorubicine. L’étude sur souris montre également un excellent effet anticancéreux associé à une diminution des effets toxiques de la doxorubicine.

  • Safe and Highly Efficient Lipid-Pro-Dexamethasone Nanoparticles for mRNA Delivery and Base Editing

    by Yan Zong, Haiping Zhong, Yuqing Wang, Yi Lin, Linxi Zhao, Xiaoyu Wang, Jianan Cai, Haoyang Lin, Yixi Xiao, Tuo Wei, et al.

    The inherent immunogenicity of mRNA lipid nanoparticles (LNPs) poses a major challenge to their application in disease treatment. In this study, we developed a series of innovative dexamethasone (DEX) prodrug ionizable lipids (DPILs) to address the need for safe and effective mRNA delivery, leading to the establishment of the Safe and Highly Efficient Lipid-pro-dexamethasone (SHIELD) LNP platform. The lead formulation, DEX-SPM-CP10 SHIELD LNP, not only markedly decreased the levels of multiple proinflammatory cytokines but also achieved mRNA delivery efficiency comparable to that of the FDA-approved SM-102 LNP. Furthermore, the SHIELD platform demonstrated universality, as incorporating specific ratios of DPILs into various LNPs targeting different organs (such as the liver, lungs, spleen, and pancreas) led to notable reductions in inflammatory responses and enhancements in mRNA expression, highlighting its superiority over strategies that incorporate free DEX. Subsequently, we investigated its application in gene editing therapy by codelivering ABEmax mRNA and sgRNA to edit the EGFP reporter gene and endogenous PCSK9 gene, as well as in protein replacement therapy through multiple injections of mRNA-SHIELD LNPs. All of these results demonstrated excellent delivery efficacy with minimal immunogenicity, fully illustrating the therapeutic potential of this platform. Taken together, the SHIELD platform offers safe and efficient mRNA delivery and has the potential to expand the therapeutic applications of mRNA-based therapies.


  • Fusion Peptide‐Incorporated Lipid Nanoparticles Boost Endosomal Escape and Enhance Cytosolic mRNA Delivery

    by Yanan Meng, Yi Lin, Zijin Luo, Xiaoqiong Tan, Xiaolu Yu, Hongyu Ren, Qiang Cheng, Chuan Fang, Tuo Wei

    The endosomal escape capability of current mRNA‐loaded lipid nanoparticles (mRNA‐LNPs) is generally low, which restricts their overall delivery efficiency. To address this limitation, we adopted a strategy inspired by the viral infection mechanism, utilizing fusion peptides to enhance the intracellular release of mRNA. Nine viral‐derived and artificial fusion peptides were co‐encapsulated within mRNA‐LNPs respectively, termed FP‐LNPs, and systematically assessed their efficacy in improving mRNA delivery. Notably, the HA2 fusion peptide from the influenza virus demonstrated a marked enhancement in mRNA delivery efficiency both in vitro and in vivo. Under acidic conditions of endosomes, HA2 collaborates with ionizable cationic lipids to facilitate endosomal membrane rupture, thereby promoting the release of mRNA into the cytoplasm and enhancing protein expression. Moreover, the incorporation of fusion peptides into various types of mRNA‐LNP formulations significantly improved their in vivo delivery efficiency of mRNA, resulting in improved gene editing outcomes in the liver and lungs. Furthermore, in a Hereditary Tyrosinemia Type 1 (HT‐1) mouse model, HA2‐LNP significantly boosted FAH protein expression in the liver and more effectively prevented body weight loss and reduced liver fibrosis. Overall, this approach offers a promising strategy for enhancing endosomal escape and boosting the delivery efficiency of mRNA, underscoring its enhanced therapeutic potential.


  • Hydrogen Bond-Assisted Two-Component Lipid Nanoparticles for Spleen-Specific mRNA Delivery

    by Qiu Wang, Yi Lin, Zijin Luo, Jiahui Xiao, Keqing Xu, Xiaolu Yu, Yanan Meng, Mengyao Li, Hongyu Ren, Fan Liu, et al.

    Conventional mRNA-LNPs typically self-assemble in acidic solutions through electrostatic interactions, necessitating long-term dialysis prior to use, which complicates the applications. In this study, a series of peptide ionizable lipids (PILs) were synthesized using solid-phase supported synthesis (SPSS) technology, aiming to utilize the amide bonds in PILs as hydrogen bond donors to form hydrogen bond-assisted mRNA-LNPs in RNase-free water, achieve extrahepatic targeted mRNA delivery, and simplify the preparation process. Through multiple rounds of optimization, a hydrogen bond-assisted two-component (2C) LNP platform composed of PILs and cholesterol was established. Among the 25 well-formulated 2C-PIL LNPs tested in vivo, 20 of them showed significant mRNA expression in the spleen, with a12K1 (2 amide bonds) and a12Orn4 (5 amide bonds) demonstrating the best performance. In addition, the two lead 2C-LNPs exhibited distinct transfection behaviors in different cell types in the spleen, indicating that suitable delivery vehicles can be tailored to meet the particular needs of specific disease indications. Notably, we found that among all K1-series (fewer hydrogen bond donors) LNPs, the efficacy of 2C-LNPs assembled based on hydrogen bond interactions was significantly higher than that of conventional four-component (4C) LNPs prepared via electrostatic interactions, suggesting that the 2C-LNPs platform may be a promising strategy to convert "inactive" LNPs into "active" LNPs. All together, these results suggest that the hydrogen bond-assisted 2C-LNPs can serve as an alternative and effective platform for spleen-targeted mRNA delivery and LNP optimization.


  • Nebulized Lipid Nanoparticles Deliver mRNA to the Liver for Treatment of Metabolic Diseases

    by Hongyu Ren, Xiaolu Yu, Mengyao Li, Zijin Luo, Yi Lin, Yanan Meng, Qiang Cheng, Tuo Wei

    An optimal administration approach is critical for effective mRNA delivery and treatment. Nebulizer inhalation offers a mild, convenient, and noninvasive strategy with high translational potential but primarily focused on lung delivery. In this study, we found that surface charges influence tissue targeting of mRNA lipid nanoparticle (mRNA-LNP) postnebulization. Charged mRNA-LNPs showed lung tropism, while neutral ones targeted the liver when administered via a microsprayer aerosolizer. Using nebulized liver-targeted LNPs (NebuLi LNPs), we successfully delivered therapeutic mRNAs for the treatment of metabolic diseases. In a Hereditary Tyrosinemia Type 1 model, fumarylacetoacetate hydrolase mRNA was effectively delivered to the liver, which helped to maintain mouse body weight, preserve liver function, and delay liver fibrosis. In a Type 2 diabetes model, dulaglutide mRNA was effectively expressed in the liver and exhibited good hypoglycemic effects. Overall, the NebuLi LNPs delivery platform offers a promising noninvasive strategy for metabolic disease treatment.